Tags

Type your tag names separated by a space and hit enter

Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.
J Clin Virol. 2020 07; 128:104428.JC

Abstract

BACKGROUND

The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations.

OBJECTIVE

This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations.

STUDY DESIGN

A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay.

RESULTS

Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert.

CONCLUSIONS

While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs.

Authors+Show Affiliations

Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. Electronic address: dag2149@cumc.columbia.edu.

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article

Language

eng

PubMed ID

32434706

Citation

Smithgall, Marie C., et al. "Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche Cobas for the Rapid Detection of SARS-CoV-2." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 128, 2020, p. 104428.
Smithgall MC, Scherberkova I, Whittier S, et al. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. J Clin Virol. 2020;128:104428.
Smithgall, M. C., Scherberkova, I., Whittier, S., & Green, D. A. (2020). Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 128, 104428. https://doi.org/10.1016/j.jcv.2020.104428
Smithgall MC, et al. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche Cobas for the Rapid Detection of SARS-CoV-2. J Clin Virol. 2020;128:104428. PubMed PMID: 32434706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. AU - Smithgall,Marie C, AU - Scherberkova,Ioana, AU - Whittier,Susan, AU - Green,Daniel A, Y1 - 2020/05/13/ PY - 2020/04/29/received PY - 2020/05/04/revised PY - 2020/05/09/accepted PY - 2020/5/22/pubmed PY - 2020/7/7/medline PY - 2020/5/22/entrez KW - COVID-19 KW - Molecular Diagnostics KW - PCR KW - Point of Care KW - SARS-CoV-2 SP - 104428 EP - 104428 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J Clin Virol VL - 128 N2 - BACKGROUND: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. OBJECTIVE: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. STUDY DESIGN: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. RESULTS: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. CONCLUSIONS: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs. SN - 1873-5967 UR - https://www.unboundmedicine.com/medline/citation/32434706/Comparison_of_Cepheid_Xpert_Xpress_and_Abbott_ID_Now_to_Roche_cobas_for_the_Rapid_Detection_of_SARS_CoV_2_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-6532(20)30170-0 DB - PRIME DP - Unbound Medicine ER -